Get started
Author

Oleksandr Korotych

Observed names: Korotych, Oleksandr, O. Korotych
ORCID: 0000-0001-8955-4197
Observed ORCID: 0000-0001-8955-4197
OpenAlex ID: A5068523762
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study
2024 · Oleksandr Korotych, Jay Achar, et al. · The Lancet Infectious Diseases · 38
Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018
2021 · Khasan Safaev, Nargiza Parpieva, et al. · International Journal of Environmental Research and Public Health · 28
PDF
Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan
2024 · Makhmujan Rashitov, Molly F Franke, et al. · Clinical Infectious Diseases · 14
PDF
Tuberculosis Notification Trends and Treatment Outcomes in Penitentiary and Civilian Health Care Sectors in the WHO European Region
2021 · Andrei Dadu, Ana Ciobanu, et al. · International Journal of Environmental Research and Public Health · 14
PDF
Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study
2022 · Yuliia Sereda, Oleksandr Korotych, et al. · International Journal of Environmental Research and Public Health · 10
PDF
Factors Associated with Unfavourable Treatment Outcomes in Patients with Tuberculosis: A 16-Year Cohort Study (2005–2020), Republic of Karakalpakstan, Uzbekistan
2021 · Jamshid Gadoev, Damin Asadov, et al. · International Journal of Environmental Research and Public Health · 9
PDF
Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study
2021 · Anastasiia Russkikh, Oleksandr Korotych, et al. · Monaldi Archives for Chest Disease · 9
PDF
Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?
2021 · Sharofiddin Yuldashev, Nargiza Parpieva, et al. · International Journal of Environmental Research and Public Health · 8
PDF
Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study
2021 · Saulius Diktanas, Oleksandr Korotych, et al. · Monaldi Archives for Chest Disease · 7
PDF
Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region
2024 · G.B. Migliori, O. Korotych, et al. · IJTLD OPEN · 3
Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova
2025 · Kasim Allel, Tom Palmer, et al. · BMJ Global Health · 2
PDF
Operational research as an instrument to address the critical gaps for effective treatment of tuberculosis in eastern Europe and central Asia
2021 · Oleksandr Korotych, Andrei Dadu, et al. · Monaldi Archives for Chest Disease · 1
PDF
Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates
2026 · Oleksandr Korotych, Helene Høgsbro Thygesen, et al. · Liver International
Frequency of serious adverse events on therapy with modified fully oral shorter treatment regimens (mSTR) for MDR/RR-TB
2023 · Elmira Gurbanova, Natalia Yatskevich, et al. · European Respiratory Journal
Operational Research to Inform Programmatic Approaches to the Management of Tuberculosis in Uzbekistan
2021 · Jamshid Gadoev, Anthony D. Harries, et al. · International Journal of Environmental Research and Public Health
PDF
Operational research to tackle TB in Eastern Europe and Central Asia: Moving forward during the COVID-19 pandemic
2021 · Askar Yedilbayev, Hayk Davtyan, et al. · The Journal of Infection in Developing Countries
PDF
Tuberculosis Research in European Countries: A Model for Programmatic Scale Up
2021 · Andrei Dadu, Oleksandr Korotych, et al. · Springer eBooks
Works count: 18
Citation count: 143
H-index: 8
I10-index: 5
Year
Topic
Type